Cumberland Pharmaceuticals (CPIX) EBITDA Margin (2010 - 2026)

Cumberland Pharmaceuticals has disclosed EBITDA Margin across 17 years of filings, most recently posting 34.27% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 34.27%, down 4530.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 17.2% (down 924.0% YoY), and the FY2025 annual result was 6.27%, up 1072.0% from the prior year.
• EBITDA Margin came in at 34.27% for Q1 2026 at Cumberland Pharmaceuticals, down from 10.02% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 11.03% in Q1 2025 to a low of 66.07% in Q4 2023.
• The 5-year median for EBITDA Margin is 17.65% (2024), against an average of 17.09%.
• Across the five-year window, EBITDA Margin jumped 4841 bps in 2024 and tumbled 4530 bps in 2026, its largest moves.
• Cumberland Pharmaceuticals' EBITDA Margin stood at 24.97% in 2022, then tumbled by 165 bps to 66.07% in 2023, then jumped by 73 bps to 17.65% in 2024, then jumped by 43 bps to 10.02% in 2025, then plunged by 242 bps to 34.27% in 2026.
• The last three EBITDA Margin figures came in at 34.27% (Q1 2026), 10.02% (Q4 2025), and 23.7% (Q3 2025), per Business Quant data.